Weight Loss in Advanced Alzheimer's Disease, Part I: Co...

Weight Loss in Advanced Alzheimer's Disease, Part I: Contributing Factors and Evaluation

Weight loss is a common occurrence in advanced Alzheimer's disease. Part I of this two-part article discusses the factors associated with the pathophysiology and progression of Alzheimer's disease that may promote weight loss, and the appropriate evaluation of weight loss and malnutrition. Factors such as abnormal eating behaviors, behavioral disturbances, oropharyngeal dysphagia, taste and smell dysfunction, and the effects of proinflammatory cytokines influence the balance between energy intake and energy expenditure, making stability more difficult to maintain and promoting a tendency toward weight loss. Many other conditions along with medication effects may also contribute to weight loss and nutritional decline. Appropriate nutritional care for the patient with Alzheimer’s disease with weight loss starts with a thorough assessment to identify all the contributing factors. The evaluation should include a review of medications, medical history, and a thorough physical examination.

This article is the first part of a two-part series.


Heidi K. White, MD, MHS. Weight Loss in Advanced Alzheimer’s Disease, Part I: Contributing Factors and Evaluation. Annals of Long-Term Care: Clinical Care and Aging: 2004;12[5]:33-37.

From the Center for the Study of Aging and Human Development and Division of Geriatrics, Department of Medicine, Duke University School of Medicine, and Geriatric Research Education and Clinical Center, Durham VAMC, Durham, NC.


INTRODUCTION

Nursing facilities that care for patients with advanced dementia are committed to providing high-quality nutritional care for all residents. These standards set forth in federal regulations state, “Based on a resident’s comprehensive assessment, the facility must ensure that a resident maintains acceptable parameters of nutritional status, such as body weight and protein levels, unless the resident’sclinical condition demonstrates that this is not possible.” [1] Alzheimer’s disease (AD) frequently involves weight loss, [2-7] which is a strong predictor of mortality. [8] Whether nutritional intervention can delay functional decline and morbidity is largely untested. However, observational data from subjects with AD indicate that weight gain is associated with a reduced risk of mortality. [8] Similar data in institutionalized subjects, including those with dementia, show that weight gain of even small amounts can improve morbidity and mortality. [9] Weight loss and subsequent malnutrition may be an unavoidable part of the natural history of end-stage AD and other dementias. However, a careful understanding of the nutritional consequence of Alzheimer’s disease, along with an appropriate assessment and a thoughtful approach to intervention, may help to avoid the complications associated with malnutrition, thus preserving a better quality of life up until death.


FACTORS IN WEIGHT LOSS

Abnormal Eating Behavior

Abnormal eating behaviors contribute to weight loss. Typical behaviors include needing frequent verbal cues to complete the eating process, verbally refusing food, pocketing food in the cheeks without swallowing, clenching teeth, and spitting food. [10,11] Abnormal eating behavior may be subtler, such as fluctuations in appetite, delusions about food (eg, believing food is poisoned), increased distractibility at mealtime, and changes in food preferences. [12] Destruction of the hippocampus and surrounding cortical areas may explain certain behaviors. In late-stage AD, plaques and tangles have been described in the hypothalamus, the neurologic center of appetite regulation. [13,14]

Dysphagia is a common manifestation of late-stage AD. [15,16] Even in early-stage AD, an increased duration of the oral and pharyngeal components of swallowing have been observed. [17]


Taste and Smell Dysfunction

Taste and smell dysfunction occurs with normal aging and can be exacerbated by medications and disease. [18,19] Although some changes in taste perception have been reported, [20] gustatory dysfunction has not been studied as thoroughly as olfactory dysfunction in Alzheimer’s disease. Multiple studies in subjects with mild to moderate Alzheimer’s disease have demonstrated deficits in odor identification. [21,22] In addition, odor threshold may become progressively more abnormal as the disease progresses. [23] Furthermore, patients with AD are often unaware of their decreased smell sensitivity. [24] Olfactory pathways are among the first areas of the brain to exhibit the typical pathology of amyloid plaques and neurofibrillary tangles. [25] Olfactory dysfunction may not be specific to Alzheimer’s disease; similar olfactory deficits have been noted in Parkinson’s disease and vascular dementia. [26]


Inflammatory Mediators

Cytokines such as interleukin-6 (IL-6) are an integral part of anorexia-cachexia syndromes in other disease states such as cancer and heart failure. [27,28] Cytokines, including IL-1, IL-6, and tumor necrosis factor (TNF)-alpha, play an important role in the inflammatory process that accompanies the hallmark changes of amyloid plaques and neurofibrillary tangles that occur with AD. [29-32] Cytokines produced by the local inflammatory reaction in the brain may be sufficient to produce changes in neurotransmitters, neuropeptides, and hypothalamic neurons to cause anorexia.


Balancing Energy Intake and Expenditure

Although inadequate oral intake is likely the primary cause of weight loss in moderate-to-severe AD, increased energy expenditure could contribute to a mismatch between energy intake and energy expenditure that leads to weight loss. It has been suggested that resting metabolic rate may be elevated in AD. However, several studies now confirm that there is no evidence that resting metabolic rate is elevated in subjects with Alzheimer’s disease compared to older adults without dementia. [33,34] The idea that physical activity in the form of behavioral disturbances (eg, pacing) may contribute to increased energy expenditure has not been supported either. [35] Unfortunately, there are no data on patients with AD during the dynamic phase of weight loss. It is evident from our work and that of others that not all patients with AD are losing weight all of the time. [8,36] There can be periods of acute weight loss, a slow gradual weight loss, and variations in weight, which may include periods of substantial weight gain.

It is possible that relatively subtle and perhaps intermittent changes in factors such as behavioral disturbance, which influence both energy intake and energy expenditure, may tip the balance toward weight loss for patients with AD. This imbalance may be multifactorial and intermittent. Rather than one particular cause or abnormality leading to weight loss, AD may lead to a condition in which changes in energy intake and expenditure are not easily compensated. Preliminary data from institutionalized subjects with AD show that body mass index (BMI) is inversely correlated with a measure of behavioral symptoms, which indicates that lower BMI was associated with higher frequency and severity of behavioral problems. [37] Certain individual behavior scores showed significant inverse correlation with weight change, indicating that as these behaviors increased over the time period weight tended to decrease.

In summary, both primary and secondary factors may contribute to weight loss in advanced AD. [38] Primary factors such as those discussed thus far are attributable to the pathophysiology of Alzheimer’s disease and may or may not be amenable to intervention. Secondary factors are not attributable to the pathophysiology of AD but are commonly encountered conditions that may contribute to weight loss, and are perhaps more amenable to intervention (Figure).


________
Figure: Primary and secondary factors that may contribute to weight loss in advanced Alzheimer’s disease.

Primary Factors
• Taste and smell dysfunction
• Proinflammatory cytokines
• Behavioral disturbances
• Abnormal eating behavior
• Oropharyngeal dysphagia


Secondary Factors
• Feeding dependence
• Acute/chronic illness
• Medication
• Restrictive diet orders
• Oral/dental problems
• Depression
• Constipation
________


EVALUATING WEIGHT LOSS AND MALNUTRITION

When to Evaluate

Periodic weight measurements are a primary resource for monitoring nutritional status and recognizing change. Most residents of nursing facilities are weighed monthly unless their condition would warrant weekly monitoring. Maintaining functional equipment, staff instruction in equipment use, and accurate systematic documentation are important. According to parameters set for the Minimum Data Set, weight loss of 5% in 1 month or 10% in 3 months is considered of clinical importance and should entail further evaluation (Table I). BMI (weight in kilograms divided by height in meters squared) is a helpful measurement of nutritional status. Older adults with a BMI of < 21 are likely to be malnourished. [39] Conditions such as pressure ulcers that increase nutritional requirements should also prompt evaluation. Although laboratory parameters such as cholesterol and albumin levels may be helpful as a means of diagnosing malnutrition and gauging the effectiveness of interventions, effective nutritional surveillance should recognize threats to nutritional status long before abnormal biochemical indices are sought. [40] Whether identified by body weight parameters or chemical indices, protein–calorie malnutrition is prevalent in long-term care. [41] Most important, all indicators should be recognized and assessed not only by the consulting dietician, but also by the nurses and physician so that a comprehensive nutrition intervention plan, which reflects the goals of care for the individual patient, can be developed and implemented.


________
Table I: Triggers for Evaluation

Weight loss of 5% in 30 days or 10% in 3 months
Body mass index ≤ 21
Pressure ulcer, infection, or other condition that increases nutritional needs

Other indicators of poor nutrition:
- Albumin < 3.4 g/dL
- Cholesterol < 160 mg/dL
- Hemoglobin < 12 g/dL
- Transferrin < 180
________


Other Illnesses

Common infections such as pneumonia or urinary tract infection will often produce anorexia. Cancer, thyroid dysfunction, and other common causes of weight loss are part of the differential diagnosis. Constipation is a common condition in institutionalized individuals because of decreased fluid intake, decreased physical activity, and medications that promote this condition. Chronic constipation can have a profound impact on appetite yet can be difficult to identify in patients with cognitive impairment. Chronic pain may also be difficult to identify but can significantly impair appetite.


Medications

Medications should be reviewed. Commonly used drugs can cause many symptoms that potentially limit caloric intake (Table II). [42] Acetylcholinesterase inhibitors, which are the primary treatment for the cognitive symptoms of AD, have several potential adverse effects including nausea, vomiting, and anorexia that may contribute to weight loss. [43,44] Additionally, galantamine has been associated with an increased incidence of weight loss. [45] Patients with dementia may not be able to voice symptoms attributable to these drugs.


________
Table II: Medications That Limit Caloric Intake

Medication Type -- Medication-Induced Symptoms
- Sedatives, opioids -- Inattention
- Antipsychotics -- Movement disorders
- Anticholinergics -- Xerostomia
- Bisphosphonates (eg, alendronate) -- Esophagitis
- Antibiotics -- Anorexia, nausea, metallic taste
- Nonsteroidal anti-inflammatory drugs -- Anorexia
- Toxic levels of drugs (eg, digoxin, theophylline) -- Nausea
- Phenothiazines, haloperidol -- Dysphagia [42]
________


Depression

Depression is a common treatable cause of weight loss in older adults. Each patient should be specifically evaluated for depression and aggressively treated when it is suspected to be present. Depression is a common occurrence in early dementia but may also be present in more advanced disease.


Don’t Forget the Mouth

Dental abnormalities such as ill-fitting dentures, tooth decay, and abscess formation may contribute to weight loss. Dry mouth and antibiotic use can lead to thrush, a yeast infection that can cause discomfort and unwillingness to eat.


Dysphagia

Patients with advanced dementia often develop serious difficulties swallowing. They may resist food being placed in the mouth, fail to manage the food bolus once it is in the mouth (oral-phase dysphagia), or aspirate when swallowing (pharyngeal-phase dysphagia). Family members and caregivers should be encouraged to report changes in eating behavior and signs of dysphagia. Coughing and choking during eating are common signs of aspiration. See Table III for additional signs of dysphagia. So-called “silent aspiration” occurs when patients with advanced dementia suffer the consequences of aspiration without any identifiable signs. A swallowing evaluation by a speech therapist that includes visualization of the swallow, either in a barium study or by fiberoptic techniques, can be helpful in determining the presence and severity of swallowing dysfunction. Although this evaluation can be helpful, many patients experience the sequelae of aspiration but do not demonstrate aspiration on such testing. Additionally, many patients who clearly aspirate on testing do not seem to suffer obvious consequences of aspiration such as weight loss or aspiration pneumonia. Some researchers have attempted to identify risk factors that might predispose patients with dysphagia to aspiration pneumonia (Table IV). [46]


________
Table III: Clinical Signs Suggestive of Dysphagia

- Cough or choke before, during, or after swallow
- Difficulty managing secretions
- Wet, gurgly voice after swallow
- Food or liquid leaking from the nose
- Pocketing food in the oral cavity
- Increased time to complete meal
- Prolonged chewing or oral preparation
________


________
Table IV: Risk Factors for Aspiration Pneumonia

- Dysphagia

- Feeding dependence

- Oral care dependence

- Number of decayed teeth

- Tube feeding

- Multiple medical diagnoses

- Number of medications
________


SUMMARY RECOMMENDATIONS

A physician should evaluate the patient with advanced AD who is losing weight, has a low BMI, or has unmet nutritional needs (eg, pressure ulcers). A thorough medical history and physical examination should be done. The physician, nutritionist, speech therapist, nurse, direct care worker, and family should contribute to the process of evaluation and the implementation of the nutrition care plan. All of these individuals must work together to ensure that weight loss and malnutrition are recognized, evaluated, and treated. The effectiveness of each intervention must be evaluated. Maintaining nutritional health will not always be possible. The goals of care must be clear to all involved, which may range from expected improvement in nutritional status to supportive and palliative care in the face of an advanced and terminal condition. The goals of care are likely to evolve as assessments are made and interventions evaluated. The nursing home medical director and primary care physicians of individual patients must provide leadership to this process, especially when alternatives to oral feeding are considered. The leadership within individual nursing facilities should discuss and determine their evaluation and implementation process for recognizing and intervening to prevent weight loss and nutritional decline. Nutritional policies and procedures need to include not only the recognition and treatment of weight loss, but also a plan for palliative and supportive care that includes careful hand feeding when end-stage dementia precludes our ability to overcome nutritional decline.

---
Part II will discuss interventions for weight loss in Alzheimer’s disease.

References

1. Omnibus Budget Reconciliation Act of 1987. Medicare and Medicaid requirements for long-term care facilities. 42 CFT. Part 483.

2. White H, Pieper C, Schmader K, Fillenbaum G. Weight change in Alzheimer’s disease. J Am Geriatr Soc 1996;44:265-272.

3. Cronnin-Stubbs D, Beckett L, Scherr P, et al. Weight loss in people with Alzheimer’s disease: A prospective population based analysis. BMJ 1997; 314:178- 179.

4. Du W, DiLuca C, Growdon JH. Weight loss in Alzheimer’s disease. J Geriatr Psychiatry Neurol 1993;6:34-38.

5. Wolf-Klein GP, Silverstone FA, Levy AP. Nutritional patterns and weight change in Alzheimer patients. Int Psychogeritr 1992;4:103-118.

6. Burns A, Marsh A, Bender DA. Dietary intake and clinical, anthropometric and biochemical indices of malnutrition in elderly demented patients and nondemented subjects. Psychol Med 1989;19:383-391.

7. White H, Pieper C, Schmader K, Fillenbaum G. A longitudinal analysis of weight change in Alzheimer’s disease. J Am Geriatr Soc 1997;45(4):531-532.

8. White H, Pieper C, Schmader K. The association of weight change in Alzheimer’s disease with severity of disease and mortality: A longitudinal analysis. J Am Geriatr Soc 1998;46:1223-1227.

9. Keller HH. Weight gain impacts morbidity and mortality in institutionalized older persons. J Am Geriatr Soc 1995;43:165-169.

10. Volicer L, Seltzer B, Rheume Y, et al. Eating difficulties in patients with probable dementia of the Alzheimer type. J Geriatr Psychiatry Neurol 1989;2:188-195.

11. Blandford G, Watkins LB, Mulvihill M, Taylor B. Correlations of aversive feeding behaviors in dementia patients. J Am Geriatr Soc 1995;43:SA10, P4.

12. Morris CH, Hope RA, Fairburn CG. Eating habits in dementia. Br J Psych 1989;154:801-806.

13. van de Nes JA, Kamphorst W, Ravid R, Swaab DF. The distribution of Alz-50 immunoreactivity in the hypothalamus and adjoining areas of Alzheimer’s disease patients. Brain 1993;116(Pt I):103-115.

14. Swaab DF, Grundke-Iqbal I, Iqbal K, et al. and ubiquitin in the human hypothalamus in aging and Alzheimer’s disease. Brain Res 1992;590:239-249.

15. Horner J, Alberts MJ, Dawson DV, Cook GM. Swallowing in Alzheimer’s disease. Alzheimer Dis Assoc Disord 1994;8(3):177-189.

16. Chouinard J, Lavigne E, Villeneuve C. Weight loss, dysphagia, and outcome in advanced dementia. Dysphagia 1998;13(3):151-155.

17. Priefer BA, Robbins J. Eating changes in mild-stage Alzheimer’s disease: A pilot study. Dysphagia 1997;12(4):212-221.

18. Schiffman SS, Pasternak M. Decreased discrimination of food odors in the elderly. J Gerontol 1979;34:73- 79.

19. Schiffman SS. Taste and smell losses in normal aging and disease. JAMA 1997;278:1357-1362.

20. Schiffman SS, Clark C, Warwick Z. Gustatory and olfactory dysfunction in dementia: Not specific to Alzheimer’s disease. Neurobiol Aging 1990;11(6):597-600.

21. Serby M, Larson P, Kalkstein D. The nature and course of olfactory deficits in Alzheimer’s disease. Am J Psychiatry 1991;148(3):357-360.

22. Koss E, Weiffenbach J, Haxby J, Friedland R. Olfactory detection and identification performance are dissociated in early Alzheimer’s disease. Neurology 1988;38(8):1228-1232.

23. Murphy C, Gilmore MM, Seery CS, et al. Olfactory thresholds are associated with degree of dementia in Alzheimer’s disease. Neurobiol Aging 1990;11:465- 469.

24. Nordin S, Monsch AU, Murphy C. Unawareness of smell loss in normal aging and Alzheimer’s disease: Discrepancy between self-reported and diagnosed smell sensitivity. J Gerontol B Psychol Sci Soc 1995;50B(4):P187-P192.

25. Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer’s disease. Neurobiol Aging 1991;12:295-312.

26. Mesholam R, Moberg P, Mahr R, Doty R. Olfaction in neurodegenerative disease: A meta-analysis of olfactory function in Alzheimer’s disease and Parkinson’s disease. Arch Neurol 1998;55(1):84-90.

27. Inui A. Cancer anorexia-cachexia syndrome: Are neuropeptides the key? Cancer Res 1999;59:4493- 4510.

28. Berry C, Clark AL. Catabolism in chronic heart failure. Eur Heart J 2000;21(7):521-532.

29. Griffin WS, Sheng JG, Roberts GW, Mrak RE. Interleukin-1 expression in different plaque types in Alzheimer’s disease: Significance in plaque evolution. J Neuropathol Exp Neurol 1995;54:276-281.

30. Griffin WS, Sheng JG, Royston MC, et al. Glial-neuronal interactions in Alzheimer’s disease: The potential role of a ‘cytokine cycle’ in disease progression. Brain Pathol 1998;8:65-72.

31. Ringheim GE, Szczepanik AM, Petko W, et al. Enhancement of beta-amyloid precursor protein transcription and expression by the soluble interleukin-6 receptor/interleukin-6 complex. Brain Res Mol Brain Res 1998;55:35-44.

32. Hull M, Berger M, Volk B, Bauer J. Occurrence of interleukin-6 in cortical plaques of Alzheimer’s disease patients may precede transformation of diffuse into neuritic plaques. Ann N Y Acad Sci 1996;777:205-212.

33. Donaldson KE, Carpenter WH, Toth MJ, et al. No evidence for a higher resting metabolic rate in non- institutionalized Alzheimer’s patients. J Am Geriatr Soc 1996;44:1232-1234.

34. Niskanen L, Piirainen M, Koljonen M, Uusitupa M. Resting energy expenditure in relation to energy intake in patients with Alzheimer’s disease, multiinfarct dementia and in control women. Age Ageing 1993;22:132-137.

35. Poehlman ET, Toth MJ, Goran MI, et al. Daily energy expenditure in free-living non-institutionalized Alzheimer’s patients: A doubly labeled water study. Neurology 1997;48:997-1002.

36. Gillette-Guyonnet S, Nourhashemi F, Andrieu S, et al. Weight loss in Alzheimer’s disease. Am J Clin Nutr 2000;71(suppl):637S-642S.

37. White HK, McConnell ES, Bales CW, Kuchibbahtia M. A 6-month observational study of the relationship between weight loss and behavioral symptoms in institutionalized AD subjects. J Am Med Dir Assoc. In press.

38. White HK. Dementia. In: Bales CW, Ritchie SC, eds. Handbook of Clinical Nutrition and Aging. Totowa, NJ: Humana Press; 2004:349-365.

39. Council for Nutritional Clinical Strategies in Long- Term Care. Clinical Guide to Prevent and Manage Malnutrition in Long-Term Care. Newtown Square, PA: Programs in Medicine; 2000. Available at: http://www.ltcnutrition.org. Accessed January 14, 2004.

40. Wilson MG, Morley JE. Nutritional assessment and support in chronic disease management. In: Bales CW, Ritchie SC, eds. Handbook of Clinical Nutrition and Aging. Totowa, NJ: Humana Press; 2004:77- 101.

41. Abbasi AA, Rudman D. Observations on the prevalence of protein-calorie undernutrition in VA nursing homes. J Am Geriatr Soc 1993;41(2):117-121.

42. Sokoloff LG, Pavlakovic R. Neuroleptic induced dysphagia. Dysphagia 1997;12:177-179.

43. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology 1998;50:136-145.

44. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: International randomized controlled trial. BMJ 1999;318(7184):633-638.

45. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54(12):2261-2268.

46. Langmore SE, Terpenning MS, Schork A, et al. Predictors of aspiration pneumonia: How important is dysphagia? Dysphagia 1998;13:69-81. ion. J Psychiatry Neurosci 2000;25(2):161-166.